2024-02-27| LicensingPartnerships

Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal

by Richard Chau
Share To

On February 26, Neomorph announced that it has inked a $1.46 billion collaboration and licensing agreement with Novo Nordisk to embark on the discovery, development, and commercialization of molecular glue degraders (MGDs). 

Founded in 2020 and venture-backed by Deerfield Management Company, one of the world’s largest dedicated healthcare investment firms, the California-based biotech brings its expertise in therapeutic innovation, while the Danish pharma giant contributes its extensive experience in diabetes, obesity, and rare blood disorders to this promising partnership.

Related article: Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials 

Understanding Molecular Glue Degraders: Revolutionizing Targeted Protein Degradation

Molecular glue degraders (MGDs) have emerged as a promising strategy for targeted protein degradation, a burgeoning area in the discovery and development of innovative therapeutics. 

This group of unique small molecules acts as bridges between proteins within cells, facilitating specific protein-protein interactions (PPIs), which allow proximity-induced protein degradation by triggering ubiquitin-proteasome activity. Having distinct biological activities and favorable physicochemical properties, MGDs open avenues for targeting proteins once deemed undruggable by conventional small molecules. 

Partnership Terms and Future Prospects

Under the terms of the agreement, Neomorph stands to receive upfront and near-term milestone payments, along with R&D funding, while also being eligible for future clinical, commercial, and sales milestone payments. The total potential deal value for multiple targets is projected to reach $1.46 billion, in addition to tiered royalties. Neomorph will spearhead discovery and preclinical activities against selected targets, with Novo Nordisk having exclusive rights to further clinical development and commercialization of the compounds, showcasing a strategic alignment of expertise and resources.

Dr. Phil Chamberlain, Co-Founder, President, and CEO of Neomorph, did not contain his excitement about the partnership with Novo Nordisk. “By combining Neomorph’s proprietary molecular glue discovery platform with Novo Nordisk’s vast experience in cardiometabolic and rare diseases, we are well positioned to develop transformative treatments in these areas. This collaboration will enable the expansion of our platform into new therapeutic areas, complementing our on-going efforts in oncology,” said Dr. Chamberlain. 

Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk, also expressed enthusiasm about the deal, highlighting Novo Nordisk’s commitment to exploring novel technology platforms for addressing chronic diseases. “We are pleased to enter this research collaboration and eager to start the scientific work on the novel class of molecular glue degraders being pioneered by Neomorph.”

© All rights reserved. Collaborate with us: [email protected]
Related Post
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
Novo Nordisk’s CLARION-CKD Trial Shut Down After Unsuccessful Results Causing Impairment Loss
Merck Buys EyeBio for $3B and Shares Global Policy Perspectives During BIO in San Diego
Topo-1 and FRα: Key Focus Areas and Major Collaborations in ADC Research – Part I
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
Assessment of Supply Chain Risk Key to Improving Medicine Access
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
Scroll to Top